Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: A new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systems

Journal of Organic Chemistry

Volumn 74, Issue 2, 2009, Pages 782-788

  Liu, Yuan ^a   Jacobs, Hollie K ^a   Gopalan, Aravamudan S ^a  

^a NEW MEXICO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACIDS; CARBON NUCLEOPHILES; ETHYL ESTERS; FUNCTIONALIZED; HARD METALS; HYDROXAMATE; HYDROXAMIC ACIDS; MACRO-CYCLIC; METAL BINDINGS; MIXED LIGANDS; N ALKYLATIONS; NEW STRATEGIES; SYNTHETIC APPROACHES;

ALKYLATION; CHELATION; ESTERS; HYDROCARBONS; IRON COMPOUNDS; LIGANDS; METAL IONS; NUCLEOPHILES; SYNTHESIS (CHEMICAL);

ORGANIC ACIDS;

BENZYLOXY CARBAMIC ACID; CARBAMIC ACID DERIVATIVE; CARBON; HALIDE; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; LIGAND; MACROCYCLIC COMPOUND; N BENZYLOXYCARBAMATE; NUCLEOPHILE; POLYHYDROXAMIC ACID; UNCLASSIFIED DRUG; CHELATING AGENT; POLYMER;

ALKYLATION; ARTICLE; CHEMICAL INTERACTION; CHEMICAL REACTION; ENERGY YIELD; METAL BINDING; METHODOLOGY; MOLECULAR STABILITY; STEREOCHEMISTRY; SYNTHESIS; CHEMISTRY;

CARBAMATES; CARBON; CHELATING AGENTS; HYDROXAMIC ACIDS; LIGANDS; POLYMERS;

EID: 60849115281     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo802410u     Document Type: Article

References (55)

1. (a) Renshaw, J. C.; Robson, G. D.; Trinci, A. P. J.; Wiebe, M. G.; Livens, F. R.; Collison, D.; Taylor, R. J. Mycol. Res. 2002, 106/10, 1123-1142.
2. (b) Dhungana, S.; Miller, M. J.; Dong, L.; Ratledge, C.; Crumbliss, A. L. J. Am. Chem. Soc. 2003, 125, 7654-7663.
3. (c) Dhungana, S.; Ratledge, C.; Crumbliss, A. L. Inorg. Chem. 2004, 43, 6274-6183.
4. (a) Tam, T. F.; Leung-Toung, R.; Li, W.; Wang, Y.; Kariman, K.; Spino, M. Curr. Med. Chem. 2003, 10, 938-995.
5. (b) Kalinowski, D. S.; Richardson, D. R. Pharmacol. Rev. 2005, 57, 547-583.
6. (a) Buss, J. L.; Torti, F. M.; Torti, S. V. Curr. Med. Chem. 2003, 10, 1021.
7. (b) Lovejoy, D. B.; Richardson, D. R. Curr. Med. Chem. 2003, 10, 1035.
8. (c) Weinberg, E. D. Adv. Appl. Microbiol. 2003, 52, 187-204.
9. (d) Richardson, D. R. Crit. Rev. Oncol. Hematol. 2002, 42, 267-281.
10. (e) Richardson, D. R. Curr. Med. Chem. 2005, 12, 2711.
11. (f) Weinberg, E. D. Hemoglobin 2008, 32, 117.
12. (a) Miller, M. J.; Zhao, G.; Vakulenko, S.; Franzblau, S.; Mollann, U. Org. Biomol. Chem. 2006, 4, 4178-4185.
13. (b) Meyer, D. Curr. Pharm. Des. 2006, 12, 1943-1947.
14. (c) Vergne, A. F.; Walz, A. J.; Miller, M. J. Nat. Prod. Rep. 2000, 17, 99-116.
15. (d) Miller, M. J.; Malouin, F. Acc. Chem. Res. 1993, 26, 241.
16. TACE inhibition: (a) Lu, Z.; Ott, G. R.; Anand, R.; Liu, R.-Q.; Covington, M. B.; Vaddi, K.; Qian, M.; Newton, R. C.; Christ, D. D.; Trzaskos, J.; Duan, J. J.-W. Bioors. Med. Chem. Lett. 2008, 18, 1958-1962.
17. (b) Ott, G. R.; Azakawa,N.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Vaddi, K.; Qian, M.; Newton, R. C.;Christ, D. D.; Trzaskos, J. M.; Decicco, C. P.; Duan, J. J.-W. Bioors. Med. Chem. Lett. 2008, 18, 694-699. Bacterial peptide deformylase inhibition:
18. (c) Jain, R.; Chen, D.; White, R. J.; Patel, D. V.; Yuan, Z. Curr. Med. Chem. 2005, 12, 1607-1621. PDE4 inhibition:
19. (d) Ochiai, H.; Ohtani, T.; Ishida, A.; Kusumi, K.; Kato, M.; Kohno, H.; Odagaki, Y.; Kishikawa, K.; Yamamoto, S.; Takeda, H.; Obata, T.; Nakai, H.; Toda, M. Bioorg. Med. Chem. 2004, 12, 4645-4665. Carbonic anhydrase inhibition:
20. (e) Ilies, M. A. ; Banciu, M. D. In Carbonic Anhydrase Its Inhibitors and Activators; CRC Press: Boca Raton, FL, 2004; Chapter 7.
21. For recent reviews on histone deacetylase inhibitors, see: (a) Jones, P.; Steinkuhler, C. Curr. Pharm. Design 2008,14, 545.
22. (b) Dokmanovic, M.; Clarke, C.; Marks, P. A. Mol. Cancer Res. 2007, 5 (10), 981.
23. (c) Marks, P. A.; Breslow, R. Nat. Biotechnol. 2007, 25, 84.
24. (d) Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Oncogene 2007, 26, 5541.
25. (e) Monneret, C. Eur. J. Med. Chem. 2005, 40,1.
26. (a) Hanessian, S.; Moitessier, N.; Gauchet, C.; Viau, M. J. Med. Chem. 2001, 44, 3066.
27. (b) Woessner, J. F.; Nagase, H. Matrix Metalloproteinases and TIMPs; Oxford University Press: New York, 2000; pp 109-125.
28. (c) Brown, P. In Matrix Metalloproteinases; Parks, W. C., Mecham, R. P., Eds.; Academic Press: San Diego, 1998; pp 243- 262.
29. (d) Kumaran, S.; Gupta, S. P. J. Enzyme Inhib. Med. Chem. 2007, 22 (1), 23.
30. (e) Skotnicki, J. S.; DiGrandi, M. J.; Levin, J. I. Curr. Opin. Drug Discovery Dev. 2003, 6/5, 742-759.
31. (f) Park, S.-K.; Han,S. B.; Lee, K.; Lee, H. J.; Kho, Y. H.; Chun, H.; Choi, Y.; Yang, J. Y.; Yoon, Y. D.; Lee, C.-W.; Kim, H. M.; Choi, H.-M.; Tae, H. S.; Lee, H.-Y.; Nam,K.-Y.; Han, G. Biochem. Biophys. Res. Commun. 2006, 341, 627-634.
32. For reviews on the use of hydroxamic acids as pharmacological agents, see: (a) Muri, E. M. F.; Nieto, M. J.; Sindelar, R. D.; Williamson, J. S. Curr. Med. Chem. 2002, 9, 1631-1653.
33. (b) Muri, E. M. F.; Nieto, M. J.; Williamson,J. S. Med. Chem. Rev. 2004, 1, 385-394.
34. (a) Koshti, N.; Gantla, V. R.; Jacobs, H. K.; Gopalan, A. S. Synth. Commun. 2002, 32/24, 3779-3790.
35. (b) Bisset, W.; Jacobs, H.; Koshti, N.; Stark,P.; Gopalan, A. React. Funct. Polym. 2003, 55/2, 109-119.
36. (c) Koshti, N. M.; Jacobs, H. K.; Martin, P. A.; Smith, P. H.; Gopalan, A. S. Tetrahedron Lett. 1994, 5157-5160.
37. Sandler, S. R.; Karo,W. Organic Functional Group Preparations, 2nd ed.; Academic Press: San Diego, 1989; Vol. 3, pp482-522.
38. For some syntheses of hydroxamic acids, see: (a) Sibi, M. P.; Hasegawa,H.; Ghorpade, S. R. Org. Lett. 2002, 4, 3343-3346.
39. (b) Sibi, M. P.; Hasegawa, H. Org. Lett. 2002, 4, 3347-3349.
40. (c) Hu, J.; Miller, M. J. J. Org. Chem. 1994, 59, 4858-4861.
41. For a review, see: (a) Yang, K.; Lou, B. Mini Rev. Med. Chem. 2003,3, 349-360.
42. (b) Volonterio, A.; Bravo, P.; Zanda, M. Tetrahedron Lett. 2001,42, 3141-3144.
43. (c) Krchnak, V.; Slough, G. A. Tetrahedron Lett. 2004,45, 4649-4652.
44. (d) Yin, Z.; Low, K.; Lye, P. Synth. Commun. 2005, 35, 2945-2950.(e) Porcheddu, A.; Giacomelli, G. J. Org. Chem. 2006, 71, 7057-59.
45. Massaro, A.; Mordini, A.; Reginato, G.; Russo, F.; Taddei, M. Synthesis2007, 3201.
46. White, J. D.; Blakemore, P. R.; Milicevic, S.; Choudhry, S. C.; Cupano,J.; Serico, L. Org. Lett. 2002, 4, 1803-1806.
47. Hernandez, N. M.; Sedano, M. J.; Jacobs, H. K.; Gopalan, A. S. Tetrahedron Lett. 2003, 44, 4035-4039.
48. Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815-3818.
49. Lithium tert-butyl acetate was generated by slow addition of tert-butyl acetate to a solution of LHMDS in THF at-78°C to avoid or reduce the self- condensation of tert-butyl acetate.
50. max = 430 nm) is formed.
51. Lambert, T. N.; Dasaradhi, L.; Huber, V. J.; Gopalan, A. S. J. Org. Chem. 1999, 64, 6097.
52. Gorden, A. E. V.; Xu, J.; Raymond, K. N. Chem. Rev. 2003, 103, 42074282.
53. Steinman, D. H.; Curtin, M. L.; Garland, R. B.; Davidsen, S. K.; Heyman, H. R.; Holms, J. H.; Albert, D. H.; Magoc, T. J.; Nagy, I. B.; Marcotte,P. A.; Li, J.; Morgan, D. W.; Hutchins, C.; Summers, J. B. Bioorg. Med. Chem.Lett. 1998, 8, 2087-2092.
54. Xue, C.-B.; Voss, M. E.; Nelson, D. J.; Duan, J. J.-W.; Cherney, R. J.; Jacobson, I. C.; He, X.; Roderick, J.; Chen, L.; Corbett, R. L.; Wang, L.; Meyer,D. T.; Kennedy, K.; DeGrado, W. F.; Hardman, K. D.; Teleha, C. A.; Jaffee,B. D.; Liu, R.-Q.; Copeland, R. A.; Covington, M. B.; Christ, D. D.; Trzaskos,J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. J. Med.Chem. 2001, 44, 2636-2660.
55. Inglesi, M.; Nicola, M.; Magnetti, S. Farmaco 1990, 45 (12), 1327-1340.